Effect of adjuvant chemotherapy in stage III cervical cancer patients treated with concurrent chemoradiation: A multicenter study

Basit Öğe Kaydı
dc.authorid0000-0002-0077-6971
dc.contributor.authorAtcı, Muhammed Mustafa
dc.contributor.authorAkagündüz, Baran
dc.contributor.authorDemir, Metin
dc.contributor.authorDönmez Yılmaz, Binnur
dc.contributor.authorAkın Telli, Tuğba
dc.contributor.authorCan, Orçun
dc.contributor.authorÇil, İbrahim
dc.contributor.authorGöktaş Aydın, Sabin
dc.contributor.authorÖzyurt, Neslihan
dc.contributor.authorÖnder, Arif Hakan
dc.contributor.authorSelvi, Oğuzhan
dc.contributor.authorSakin, Abdullah
dc.date.accessioned2022-05-27T09:00:45Z
dc.date.available2022-05-27T09:00:45Z
dc.date.issued2022
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractINTRODUCTION: A significant proportion of cervical cancer (CC) patients are diagnosed at a locally advanced stage. Concurrent chemoradiotherapy (CCRT) is the cornerstone of treatment for patients with locally advanced CC. However, the role of adjuvant chemotherapy (AC) after CCRT is controversial. In this study, we analyzed the efficacy of AC after CCRT in stage III CC patients. METHODS: We performed a multicenter, retrospective analysis of 139 International Federation of Gynecology and Obstetrics stage III CC patients treated with CCRT of whom 45.3% received AC. Our goal was to determine the impact of AC on survival in these patients. RESULTS: Five-year progression-free survival (PFS) was 37.5% and 16% in patients receiving CCRT with and without AC, respectively (p = 0.008). Median PFS was 30.9 months (CI 95% 14.8-46.9) and 16.6 months (CI 95% 9.3-23.9) in patients receiving CCRT with and without AC, respectively. Five-year overall survival (OS) was 78.2% and 28.4% in patients receiving CCRT with and without AC, respectively (p < 0.001). Median OS was 132.2 months (CI 95, %66.5-197.8) and 34.9 months (CI 95% 23.1-46.7) in patients receiving CCRT with and without AC, respectively. CONCLUSION: Our study suggests that AC provides OS and PFS benefit in stage III CC patients. Larger studies are needed to identify subgroups of patients who would benefit from AC.
dc.identifier.citationAtcı, M. M., Akagündüz, B., Demir, M., Dönmez Yılmaz, B., Akın Telli, T., Can, O. ... Sakin, A. (2022). Effect of adjuvant chemotherapy in stage III cervical cancer patients treated with concurrent chemoradiation: A multicenter study. Oncology Research and Treatment, 45(5), 254-261. https://doi.org/10.1159/000521980
dc.identifier.doi10.1159/000521980
dc.identifier.endpage261
dc.identifier.issn2296-5262
dc.identifier.issue5
dc.identifier.pmid35034017
dc.identifier.scopus2-s2.0-85129996780
dc.identifier.scopusqualityQ2
dc.identifier.startpage254
dc.identifier.urihttps://doi.org/10.1159/000521980
dc.identifier.urihttps://hdl.handle.net/20.500.12511/9473
dc.identifier.volume45
dc.identifier.wos000833355100003en_US
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorGöktaş Aydın, Sabin
dc.language.isoen
dc.publisherNLM (Medline)
dc.relation.ispartofOncology Research and Treatmenten_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAdjuvant Chemotherapy
dc.subjectCervical Cancer
dc.subjectStage III
dc.titleEffect of adjuvant chemotherapy in stage III cervical cancer patients treated with concurrent chemoradiation: A multicenter study
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu